Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00051974 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 155
- Enrollment target
- 20
- Study locations
NCT00051974: Completed Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Millennium Pharmaceuticals.
NCT00051974 is a Phase 2 study of Non-Small Cell Lung Cancer that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 155 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (76% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00051974, a Phase 2 study of Non-Small Cell Lung Cancer, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 155 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate how tumors in patients with non-small cell lung cancer respond to treatment with VELCADE alone versus VELCADE given with docetaxel and also to see what effects (good and bad) it has on you and your cancer.
Conditions Studied
Interventions
- DRUG VELCADE™ (bortezomib) for Injection (formerly PS-341)
Study Locations (20)
Missouri
- DBA Kansas City Cancer Centers - Kansas City
- St. Louis University Health Sciences Center - St Louis
- Washington University, Barnard Cancer Center - St Louis
California
- Cedars-Sinai Comprehensive Cancer Center - Los Angeles
- UCLA Medical Center Thoracic Malignancy - Los Angeles
Florida
- Univeristy of Florida Shands Cancer Center - Gainesville
- Sylvester Comprehensive Cancer Center - Miami
Georgia
- Winship Cancer Institute - Atlanta
- Atlanta VAMC - Decatur
North Carolina
- Carolinas Hematology-Oncology Associates - Charlotte
- Duke University Medical Center - Durham
Alabama
- U of Alambama at Birmingham Comprehensive Cancer Center - Birmingham
Colorado
- University of Colorado Health Sciences Center - Aurora
Connecticut
- Yale University School Of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2002-12 |
| Phase | Phase 2 |
What the finished NCT00051974 record still lists
NCT00051974 is an interventional study that assigns participants to a tested intervention. The registered 155 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which VELCADE™ (bortezomib) for Injection (formerly PS-341) is the first listed.
NCT00051974 names 20 study sites across 14 states, led by Missouri, California, Florida.
Frequently Asked Questions
What is clinical trial NCT00051974 about?
NCT00051974 is a clinical study titled "Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer". The purpose of this study is to evaluate how tumors in patients with non-small cell lung cancer respond to treatment with VELCADE alone versus VELCADE given with docetaxel and also to see what effects (good and bad) it has on you and your cancer.
What is the current status of trial NCT00051974?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2002-12.
What conditions does trial NCT00051974 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT00051974?
The interventions under investigation include: VELCADE™ (bortezomib) for Injection (formerly PS-341) (DRUG).
Who is sponsoring clinical trial NCT00051974?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00051974 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00051974's enrollment target sits among peer trials
155 195th of 454 higher than 260 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03223610 · 155 participants · Phase 1
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- NCT05072483 · 155 participants
Natural History Study of CADASIL
- NCT05086497 · 155 participants · NA
WBSI Guided Personalized Delivery of TTFields
- NCT05412069 · 155 participants · NA
Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia